Like human gliomas, the rat 9L gliosarcoma secretes the immunosuppressive transforming growth factor p (TGF-P3). Using the 9L model, we tested our hypothesis that genetic modification of glioma cells to block TGF-P8 expression may enhance their immunogenicity and make them more suitable for active tumor immunotherapy. Subcutaneous immunizations of tumor-bearing animals with 9L cells genetically modified to inhibit TGF-j3 expression with an antisense plasmid vector resulted in a significantly higher number of animals surviving for 12 weeks (11/11, 100%) 
13%) or 9L cells transduced with an interleukin 2 retroviral
vector (3/10, 30%) (P < 0.001 for both comparisons). Histologic evaluation of implantation sites 12 weeks after treatment revealed no evidence of residual tumor. In vitro tumor cytotoxicity assays with lymph node effector cells revealed a 3-to 4-fold increase in lytic activity for the animals immunized with TGF-P3 antisense-modified tumor cells compared to immunizations with control vector or interleukin 2 gene-modified tumor cells. These results indicate that inhibition of TGF-f3 expression significantly enhances tumor-cell immunogenicity and supports future clinical evaluation of TGF-P antisense gene therapy for TGF-p-expressing tumors.
Brain tumors are responsible for significant morbidity and mortality in both pediatric and adult populations (1) . While glioblastoma multiforme tumors rarely metastasize outside of the nervous system, they diffusely infiltrate brain tissues (2) and cannot be cured by surgical resection. Surgery and highdose radiation provide the best standard therapy; however, these treatments are not curative and prognosis remains poor (2) . Therefore, development of new therapies for these tumors is essential.
Glioma cells express major histocompatibility complex class I and class II molecules (3) , as well as tumor-associated antigens that have been demonstrated to stimulate anti-tumor immune responses and thus are good tumor vaccine candidates (4, 5) . However, several studies have demonstrated the secretion of an immunosuppressive factor by glioma cells that was subsequently identified as transforming growth factor P (TGF-/3) (6-9).
TGF-3, has been shown to exert several potent immunosuppressive effects (10, 11) , including the inhibition of cytotoxic T-lymphocyte activation (6, (12) (13) (14) . We (16) . Pools of clones were selected with hygromycin at 200 ,ug/ml (Sigma). TGF-3 secretion was measured by the previously described TF-1 cell bioassay (17) . The (17) . To confirm the specificity of TF-1 growth inhibition by TGF-13, the conditioned 9L supernatants were incubated with neutralizing concentrations of turkey anti-TGF-f3 antiserum. Normal (nonimmune) turkey sera was used as a negative control. Standard curves generated with known concentrations of purified TGF-13 (Sigma) served as a positive control and permitted quantification of TGF-3 levels in the test samples. Antisense inhibition of TGF-,3 has been maintained for >1 yr and has been confirmed by the TF-1 bioassay.
IL-2 vector. The construction of LNCX/IL-2 retroviral has been described (18) . Virus-containing supernatant from PA317/LNCX/IL-2 packaging cell line was used to transduce the 9L and TGF-/32 antisense-modified 9L cell cultures as described (18) . The levels of interleukin 2 (IL-2) in tissue culture supernatants of IL-2-transduced cells were measured by previously described ELISA, and the IL-2 biological activity was confirmed as described (18 (20) .
Cell-Mediated Cytotoxicity Assays. Standard chromiumrelease assays (21) (Fig. 3A) . After (Fig. 3B) . The animals immunized with TGF-f3 antisense-modified tumor cells generally had smaller tumors at the second tumor injection sites, which were characterized by extensive necrosis (Fig. 3C) . None of these animals had evidence of residual tumor at the original tumor-implantation site.
Cell-Mediated Cytotoxicity Assays. Standard chromiumrelease assays were used to assess the antitumor immune responses generated by immunization with inocula described in Table 1 . Immune lymphocytes from the lymph nodes of these rats were stimulated in vitro with unmodified 9L cells and tested for their ability to kill unmodified 9L target cells. As shown in Fig. 4 (Fig. 4) Suppression of cellular immunity has long been observed in patients with glioblastoma (8) (9) (10) . Incubation of peripheral blood lymphocytes with the supernatant of glial tumor cells renders the lymphocytes unresponsive to mitogenic activation (6, 7, 22) . This initially described glioblastoma-derived suppressor factor was later identified as TGF-,3 (23) . TGF-83 is a potent immunosuppressive agent that inhibits many immune system functions (10, 11) . In particular, TGF-,1 inhibits the activation of cytotoxic T cells and B cells and through a feedback mechanism results in deactivation of NK and LAK cells (6, 12-14, 24-27, 30) . Immune suppression mediated by TGF-3 appears to be due, in part, to impairment of highaffinity IL-2-receptor function and expression (6, (12) (13) (14) 28) . These are important elements for the initiation and maintenance of T-cell activation and function (14) . TGF (27) . The use of TGF-P antisense-modified 9L as target cells in these assays had no effect on effector cell-mediated killing, suggesting that TGF-/3 does not suppress the function of activated effector cells. This finding is consistent with previous reports that the immunosuppressive effects of TGF-,3 are most pronounced on afferent components of immune response induction (26, 29, 30 (32) (33) (34) . These protective immune responses were not observed after immunization with unmodified wild-type tumor cells (32) (33) (34) 
